Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents

British Journal of Pharmacology

Volumn 149, Issue 1, 2006, Pages 92-99

  Kjellev, S ^a   Nexo E ^b   Thim, L ^a   Poulsen, S S ^c  

^a NOVO NORDISK A S   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Autoradiography; In situ hybridization; Mucus; Trefoil factor 2; Trefoil factor 3; Viscosity

Indexed keywords

CARBACHOL; TREFOIL FACTOR 2; TREFOIL FACTOR 3; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW MEASUREMENT; GENERAL ANESTHESIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CONTENT; STOMACH MUCOSA; STOMACH SECRETION; VISCOSITY;

ANIMALS; AUTORADIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL CONTENTS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; PEPTIDES; RATS; RATS, WISTAR; STOMACH; TISSUE DISTRIBUTION; VISCOSITY;

EID: 33748030426     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706840     Document Type: Article

References (28)

1. Babyatsky MW, Debeaumont M, Thim L, Podolsky DK (1996). Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110: 489-497.
2. Chinery R, Cox HM (1995a). Immunoprecipitation and characterization of a binding protein specific for the peptide, intestinal trefoil factor. Peptides 16: 749-755.
3. Chinery R, Playford RJ (1995b). Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Lond) 88: 401-403.
4. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK (1994). Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 94: 376-383.
5. Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK et al. (2002). TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109: 193-204.
6. Hoffmann W, Jagla W, Wiede A (2001). Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 16: 319-334.
7. Jagla W, Wiede A, Hinz M, Dietzmann K, Gulicher D, Gerlach KL (1999). Secretion of TFF-peptides by human salivary glands. Cell Tissue Res 298: 161-166.
8. Kindon H, Pothoulakis C, Thim L, Lynch-devaney K, Podolsky DK (1995). Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 109: 516-523.
9. Marchbank T, Westley BR, May FE, Calnan DP, Playford RJ (1998). Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol 185: 153-158.
10. Mashimo H, Podolsky DK, Fishman MC (1995). Structure and expression of murine intestinal trefoil factor: high evolutionary conservation and postnatal expression. Biochem Biophys Res Commun 210: 31-37.
11. Mashimo H, Wu DC, Podolsky DK, Fishman MC (1996). Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265.
12. Newton JL, Allen A, Westley BR, May FEB (2000). The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut 46: 312-320.
13. Ogata H, Podolsky DK (1997). Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine. Am J Physiol 273: G348-G354.
14. Playford RJ, Marchbank T, Chinery R, Evison R, Pignatelli M, Boulton RA et al. (1995). Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 108: 108-116.
15. Poulsen SS, Kissow H, Hare K, Hartmann B, Thim L (2005). Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept 126: 163-171.
16. Poulsen SS, Thulesen J, Christensen L, Nexo E, Thim L (1999). Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 45: 516-522.
17. Poulsen SS, Thulesen J, Hartmann B, Kissow HL, Nexo E, Thim L (2003). Injected TFF1 and TFF3 bind to TFF2-immunoreactive cells in the gastrointestinal tract in rats. Regul Pept 115: 91-99.
18. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K et al. (1994). The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 145: 782-791.
19. Tanaka S, Podolsky DK, Engel E, Guth PH, Kaunitz JD (1997). Human spasmolytic polypeptide decreases proton permeation through gastric mucus in vivo and in vitro. Am J Physiol 272: G1473-G1480.
20. Taupin D, Podolsky DK (2003). Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4: 721-732.
21. Thim L (1989). A new family of growth factor-like peptides. 'Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS Lett 250: 85-90.
22. Thim L, Madsen F, Poulsen SS (2002). Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 32: 519-527.
23. Thim L, Norris K, Norris F, Nielsen PF, Bjorn SE, Christensen M et al. (1993). Purification and characterization of the trefoil peptide human spasmolytic polypeptide (hSP) produced in yeast. FEBS Lett 318: 345-352.
24. Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK (1995). Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 34: 4757-4764.
25. Tomasetto C, Masson R, Linares JL, Wendling C, Lefebvre O, Chenard MP et al. (2000). pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 118: 70-80.
26. Tomita M, Itoh H, Ishikawa N, Higa A, Ide H, Murakumo Y et al. (1995). Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes. Biochem J 311 (Part 1), 293-297.
27. Vestergaard EM, Brynskov J, Ejskjaer K, Clausen JT, Thim L, Nexo E et al. (2004). Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 64: 146-156.
28. Vestergaard EM, Poulsen SS, Gronbaek H, Larsen R, Nielsen AM, Ejskjaer K et al. (2002). Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 48: 1689-1695.